Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.60 |
| ▸ | ESR1 | P03372 | 2/20 | 0.60 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.58 |
| ▸ | WIZ | O95785 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27423839 | 1.00 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL24735305 | 1.00 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL29841272 | 1.00 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| Hydrochloric Acid SCHEMBL22581049 | 0.99 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| Hydrochloric Acid SCHEMBL22581000 | 0.99 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| Hydrochloric Acid SCHEMBL22581144 | 0.99 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL27308323 | 0.98 | CRBN (0.61) | CRBNESR1IKZF2WIZIKZF1 | |
| Hydrochloric Acid SCHEMBL30906238 | 0.97 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL31129474 | 0.97 | CRBN (0.62) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL27314019 | 0.93 | CRBN (0.57) | CRBNESR1IKZF2WIZIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4626555-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-02 | — | — | US | disclosed |
| WO-2024263781-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| US-20240374588-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| WO-2023088245-A1 | DEGRADATION AGENT AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022159688-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021055756-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20200339572-A1 | NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | CRBN 2486/4885ESR1 1375/4885IKZF2 4522/4885 |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | CRBN 3/4885ESR1 3900/4885IKZF2 542/4885 |
| US-20240374588-A1 | IRAK4 PROTACS | IRAK4, IRAK2, IRAK3 | CRBN 99/4885ESR1 879/4885IKZF2 56/4885 |
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | EGFR, ERBB2, ERBB4 | CRBN 2544/4885ESR1 860/4885IKZF2 4693/4885 |
| US-20200339572-A1 | NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF | CDK4, CDK6, CCNI | CRBN 1124/4885ESR1 1123/4885IKZF2 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.